Lantheus (LNTH) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lantheus is the larger company by market cap ($6.68 billion vs $573.2 million), about 11.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | QUIT |
|---|---|---|
| Share price | $102.10 | $5.56 |
| Market cap | $6.68B | $573.25M |
| 1-day change | 0.00% | -5.28% |
| YTD return | +53.42% | — |
| 1-year return | +82.91% | — |
| 5-year return | +266.08% | — |
| P/E ratio (TTM) | 25.40 | — |
| Forward P/E | 15.34 | — |
| EPS (TTM) | $4.02 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | — |
| Revenue growth (YoY) | +0.50% | — |
| Net income (latest FY) | $233.56M | $-54.65M |
| Gross margin | 61.10% | — |
| Operating margin | 20.16% | — |
| Net margin | 15.15% | — |
| 52-week high | $111.86 | $8.64 |
| 52-week low | $54.94 | $2.62 |
| Distance from 52-week high | -8.73% | -35.65% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +3.81% | +162.23% |
| Average volume | 1.02M | 1.38M |
| Shares outstanding | 65.40M | 103.10M |
| Employees | 1,193 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 11.6 times larger than Achieve Life Sciences by market value ($6.68B vs $573.25M).
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
LNTH vs QUIT FAQ
Which is bigger, Lantheus or Achieve Life Sciences?
Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $573.25M for Achieve Life Sciences (QUIT).
Are Lantheus and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.